Exelixis gains US OK for Cometriq in metastatic medullary thyroid cancer
This article was originally published in Scrip
As expected, the US FDA gave its OK for Exelixis to market its tyrosine kinase inhibitor Cometriq (cabozantinib) as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) – a decision that came after the US markets closed on 29 November.
You may also be interested in...
Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.